How many drugs treat Vernal keratoconjunctivitis?

Drug Landscape tracks 4 marketed treatments for Vernal keratoconjunctivitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/vernal-keratoconjunctivitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vernal keratoconjunctivitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vernal keratoconjunctivitis (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Vernal keratoconjunctivitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Alomide	LODOXAMIDE	Novartis	Mast Cell Stabilizer	G-protein coupled receptor 35	1993-01-01
Intal	cromoglicic acid	Pfizer	Mast Cell Stabilizer	G-protein coupled receptor 35	1982-01-01
Cromoglycate	Cromoglycate	Vishwajit Nimgaonkar, MD PhD		Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20
Cromoglicate	Cromoglicate	LEO Pharma		Protein S100-P, G-protein coupled receptor 35, Taste receptor type 2 member 20

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

LEO Pharma · 1 drug in Vernal keratoconjunctivitis
Novartis · 1 drug in Vernal keratoconjunctivitis
Pfizer · 1 drug in Vernal keratoconjunctivitis
Vishwajit Nimgaonkar, MD PhD · 1 drug in Vernal keratoconjunctivitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Vernal keratoconjunctivitis:

Cite this brief

Drug Landscape (2026). Vernal keratoconjunctivitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/vernal-keratoconjunctivitis. Accessed 2026-06-10.

Vernal keratoconjunctivitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing